anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To increase water resistance and water repellency of produced emulsion by compounding water-swelling clay mineral, quaternary ammonium salt type cation surfactant, aq. phase, oil phase contg. specified org. silicone resin, etc. CONSTITUTION:The water-in-oil type emulsion compsn. is prepd. by mixing water-swelling clay mineral, quaternary ammonium salt type cation surfactant, one or more kinds of polyoxyalkylene modified organopolysiloxanes, aq. phase, one or more kinds of org. silicone resins consisting of units of formula I (where, R is 1-6C hydrocarbon residue or phenyl group and n is 1.0-1.8). The quaternary ammonium salt type cation surfactant content is preferably 40-140 miliequiv. to 100g water-swelling clay mineral.
PURPOSE: A pharmaceutical composition for treating asthma is provided to be used as a cell therapeutic agent for treating asthma using bone marrow-derived allergen-stimulated dendritic cells. CONSTITUTION: A pharmaceutical composition for treating asthma contains bone marrow-derived allergen-stimulated dendritic cells as an active ingredient. The allergen is egg yolk. The composition contains 4x10^5 to 6x10^5 dendritic cells. The dendritic cells suppress IL-4 and IL-5 generation and promote IFN-gamma and IL-10 generation to treat asthma. A cell therapeutic agent for treating asthma contains the composition.
Cytomegalovirus (CMV) is the most important infection in transplant patients and it is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver; when CMV infection becomes serious enough to cause symptoms, it is called CMV disease. Some patients require treatment while others will clear the virus on their own.

QuantiFERON-CMV (QFT-CMV) is a blood test that measures CMV-specific cell-mediated immunity. This test was able to predict that patients with low cell-mediated immunity are at greater risk for developing CMV disease. In this study, QFT-CMV will be used to make a decision regarding CMV treatment. The QFT-CMV test will be performed at the first detection of CMV, at end of antiviral therapy and one month post-therapy. The end-of-therapy results will be available to clinicians and study investigators within one week of collection. Based on the result, a decision will be made to continue with prolonged antiviral therapy. Patients that show weak cell-mediated immunity against CMV will be given secondary antiviral prophylaxis, while patients with good cell-mediated immunity will have their therapy stopped. Patients will continue to be monitored three months after the last QFT-CMV test for recurrent CMV viremia.

This study will also attempt to evaluate the predictive value of the QuantiFERON-Monitor (QFT-Monitor) assay. QFT-Monitor is a recently developed non-pathogen specific immune assay: it is based on immune activation of both innate and adaptive immunity. The investigators hypothesize that stimulation of both the innate and adaptive immunity may predict global immune function and also be predictive of CMV reactivation. The investigators plan to perform the QFT-Monitor assay in parallel to the QFT-CMV test to determine the test characteristics and cut-off values in predicting global immune function. This test will be collected and tested in batches. Therefore, the results will not influence clinical decisions.
Named for their potent ability to interfere and protect against viral infections, interferons (IFNs) have many regulatory effects on the immune system.1 Of the members of the two classes of these compounds, IFN-γ has the most diverse and powerful immune effects. Studies have mostly evaluated IFN-γ interactions with cells of adaptive immunity, including macrophages and lymphocytes. Effects on innate immunity, particularly polymorphonuclear leukocytes or neutrophils and monocytes are less well studied. However, investigations have suggested that IFN-γ may be involved in signal transduction, gene expression, the respiratory burst and neutrophil NADPH oxidase (Nox2) activity, phagocytosis, motility, microbicidal activity, and apoptosis. Not all of these functions are enhanced by IFN-γ; but the clinical use of this cytokine has been driven, in part by these results. For example, the primary motivation for initiating investigation of its beneficial clinical effects in Chronic Granulomatous Disease (CGD) was its effects on Nox2 activity.2 Most data in this area was based on studies using differentiated neutrophils from peripheral blood.1 However, the phenotype of neutrophils developed under the influence of this cytokine, not just changes expressed by exposure of differentiated cells to IFN-γ, is critical to understanding the physiologic effects of IFN-γ and the broad applications for its use in treatment of a range of human diseases. To expand their understanding of the role of IFN-γ in the development and functional integrity of the neutrophil, the investigators have completed a series of studies with PLB-985 cells in an in vitro culture system of myeloid cells. In this proposal, the investigators will evaluate innate immune activation and phagocyte function in healthy adult volunteers who are receiving IFN-γ.
This is a first-in-human, randomized, multi-center study in participants with prion disease. Eligible participants will receive ION717 and placebo. The study will consist of a screening period of up to 6 weeks, a 30-week double-blind treatment period, a 70-week open-label extension period and a 32-week post-treatment period. During the double-blind period, the order of ION717 and placebo doses will be randomized and blinded to participants, study sites and the Sponsor. During the open-label extension period, all participants will receive ION717. Multiple dose levels will be tested.
PURPOSE:An agent for growing and nourishing hair containing an oxidizing agent as an active ingredient such as stabilized chlorine dioxide, potassium bromate, etc., substances to suppress or to prevent an enzymatic action of 5alpha reductase, a reductase, occurring in the sebaceous gland. CONSTITUTION:An agent for growing and nourishing hair containing an oxidizing agent such as stabilized chlorine dioxide, potassium bromate, etc. as an active ingredient. Testosterone, male hormone, is formed by the testicles, sent directly to the sebaceous gland by the circulation, and converted by 5alpha reductase, a reductase occurring in the sebaceous gland, into 5alpha dehydrotestosterone, strong male hormone, which suppresses the cell division of hair metrocyte to form baldness. The agent for growing and nourishing hair suppresses the activity of 5alpha reductase, a reductase, contained in it, and promotes the nourishment and regeneration of hair. The amount of the stabilized chlorine dioxide used is preferably 250ppm.
PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
PURPOSE OF THE REVIEW: With increased access and decriminalization of cannabis use, cases of IgE-dependent cannabis allergy (CA) and cross-reactivity syndromes have been increasingly reported. However, the exact prevalence of cannabis allergy and associated cross-reactive food syndromes (CAFS) remains unknown and is likely to be underestimated due to a lack of awareness and insufficient knowledge of the subject among health care professionals. Therefore, this practical roadmap aims to familiarize the reader with the early recognition and correct management of IgE-dependent cannabis-related allergies. In order to understand the mechanisms underlying these cross-reactivity syndromes and to enable personalized diagnosis and management, special attention is given to the molecular diagnosis of cannabis-related allergies.
RECENT FINDINGS: The predominant signs and symptoms of CA are rhinoconjunctivitis and contact urticaria/angioedema. However, CA can also present as a life-threatening condition. In addition, many patients with CA also have distinct cross-reactivity syndromes, mainly involving fruits, vegetables, nuts and cereals. At present, five allergenic components of Cannabis sativa (Can s); Can s 2 (profilin), Can s 3 (a non-specific lipid protein), Can s 4 (oxygen-evolving enhancer protein 2 oxygen), Can s 5 (the Bet v 1 homologue) and Can s 7 (thaumatin-like protein) have been characterized and indexed in the WHO International Union of Immunological Sciences (IUIS) allergen database. However, neither of them is currently readily available for diagnosis, which generally starts by testing crude extracts of native allergens. The road to a clear understanding of CA and the associated cross-reactive food syndromes (CAFS) is still long and winding, but well worth further exploration.
Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. They will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
The role of circular RNAs (circRNAs) in neuropathic pain is linked to the fundamental physiological mechanisms involved. However, the exact function of circRNAs in the context of neuropathic pain is still not fully understood. The functional impact of circGRIN2B on the excitability of dorsal root ganglion (DRG) neurons was investigated using siRNA or overexpression technology in conjunction with fluorescence in situ hybridization and whole-cell patch-clamp technology. The therapeutic efficacy of circGRIN2B in treating neuropathic pain was confirmed by assessing the pain threshold in a chronic constrictive injury (CCI) model. The interaction between circGRIN2B and NF-κB was examined through RNA pulldown, RIP, and mass spectrometry assays. CircGRIN2B knockdown significantly affected the action potential discharge frequency and the sodium-dependent potassium current flux (SLICK) in DRG neurons. Furthermore, knockdown of circGRIN2B dramatically reduced the SLICK channel protein and mRNA expression in vivo and in vitro. Our research confirmed the interaction between circGRIN2B and NF-κB. These findings demonstrated that circGRIN2B promotes the transcription of the SLICK gene by binding to NF-κB. In CCI rat models, the overexpression of circGRIN2B has been shown to hinder the progression of neuropathic pain, particularly by reducing mechanical and thermal hyperalgesia. Additionally, this upregulation significantly diminished the levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α in the DRG. Upon reviewing these findings, it was determined that circGRIN2B may mitigate the onset of neuropathic pain by modulating the NF-κB/SLICK pathway.
A toxoid is derived from a toxin in which an arginine residue within the toxin has undergone reaction with an alpha-dicarbonyl compound of general structure RC(O)C(O)Râ, wherein R and Râ are each selected from H, alkyl, substituted alkyl, aryl or substituted aryl group. Examples of such compounds are glyoxal, phenylglyoxal, butanedione and 1,2-cyclohexanedione. Preferably at least one of R and Râ is/are H; ie the compound preferably has at least one aldehyde group. The toxin may be derived from a plant (e.g. ricin), an animal (e.g. snake venom) or bacterium (e.g. botulinum toxin, tetanus toxin, diphtheria toxin, cholera toxin, Bordetella pertusis toxin, Pseudomonas endotoxin, shiga or shiga-like toxin, anthrax toxin or Staphylococcal enterotoxin B (SEB). The toxoids may be used as a medicament for prophylactic or therapeutic treatment of intoxication by the toxin. Alternatively, they may be used for the production of antitoxin antibodies by injecting the toxoid into an animal and harvesting the antibodies from the serum. Antitoxin antibodies thus produced may be used for the prophylactic or therapeutic treatment of intoxication by the toxin.
COPD is one of the leading causes of death in the United States and results in increased healthcare costs and disability. Smoking is the main determinant of COPD development and continued use increases mortality as compared to those who have stopped smoking. Research has indicated that cigarette smoking may play a role in attempts to regulate distressing emotional experiences and thus, may be an important transdiagnostic process underlying continued smoking behavior among adults with COPD. The current study investigated the role of ER difficulties in relation to smoking status and cigarettes smoked per day among adults with COPD. This cross-sectional study included a sample was adults with COPD (N = 320). Participants self-reported current smoking status, daily smoking, and the Difficulties in Emotion Regulation Scale. All analyses were adjusted for age, sex, probable depression, probable anxiety, and dyspnea severity. DERS total scores were associated with greater odds of current smoking. With the exception of impulsivity, all other dimensions of emotion regulation were significantly associated with current smoking. Greater difficulties in emotional awareness were associated with greater cigarettes smoked per day. However, neither the DERS total score nor any other dimensions of emotional regulation were significantly associated with cigarettes smoked per day. The present study provides preliminary data linking ER difficulties to smoking behavior among adults with COPD. If corroborated by future research, these findings suggest that ER might be a potential target for smoking cessation programs among adults with COPD.
Juvenile-onset Huntington's disease (HD) is a rare subset of HD with symptom-onset before the age of 18. In contrast to the adult population, children present early-on with behavioral, psychiatric, and cognitive symptoms, in addition to a diverse spectrum of movement disorders. This poses a distinct challenge in diagnosis and management. We here describe the spectrum of movement disorders, accompanied with detailed video recordings, in seven cases of juvenile-onset HD. Our findings highlight early cognitive and behavioral symptoms, preceding motor symptoms. The diverse movement disorder phenotypes included dystonia, Parkinsonism, myoclonus, and chorea, findings which underscore the heterogeneity of presenting symptoms.
A method of administering insulin includes receiving blood glucose measurements (BG) of a patient (10) at a data processing device (112) from a glucometer (124). Each blood glucose measurement (BG) is separated by a time interval (TNext) and includes a blood glucose time ( BG-Time) associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information (208a) at the data processing device and selecting a subcutaneous insulin treatment program for tube-fed patients (1000) from a collection of subcutaneous insulin treatments (900, 1000, 1100, 1200, 1300, 1400). The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment program for tube-fed patients (1000).
The present invention is directed toward peptide analogues of human myelin basic protein. The peptide analogue is at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. The analogues are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating multiple sclerosis.
OBJECTIVE: Partial upper sternotomy is preferred for isolated aortic valve replacement because of its optimal surgical visibility and favorable cosmetic outcomes; however, it is not commonly used for aortic root surgery, and the conventional median sternotomy is still the preferred method for most surgeons. We aimed to compare the safety and effectiveness of a minimally invasive approach (partial sternotomy [PS]) and conventional approach (median sternotomy [FS]) for aortic root surgery.
METHODS: Patients who underwent aortic root surgery at our hospital from 2016 to 2021 were retrospectively enrolled and divided into two groups. After propensity score matching, the conventional group included 156 patients and the minimally invasive group-57 patients.
RESULTS: Bicuspid aortic valves were observed in 63 (40.4%) and 33 (57.9%) patients in the FS and PS groups, respectively. Valve-sparing surgery was performed on 69 (44.2%) and 30 (52.6%) patients in the FS and PS groups, respectively. The minimally invasive approach was beneficial in terms of blood loss during the first 24 h after surgery (p = 0.029) and postoperative blood transfusion (p = 0.023). The survival rates and freedom from reoperation or severe aortic regurgitation after the David procedure were comparable between the standard and minimally invasive groups (p = 0.25; p = 0.66) at mid-term follow-up.
CONCLUSIONS: A minimally invasive approach for aortic root surgery can be safely performed as the standard approach. Partial upper sternotomy has the advantage of lower blood loss in the early postoperative period and does not negatively affect the results of valve-sparing root replacement.
PURPOSE:To eliminate the leakage of the filled contents and deterioration due to oxidation by coating the respective nuclei consisting of a filling substance or a part of nuclei or other nuclei with film substances having different compositions, making the capsule seamless. CONSTITUTION:The impact of a regular intermittent stream of a liq. medium from an intermittent stream nozzle 8 is exerted on a composite jet stream, hence recesses are successively formed from the tip at regular intervals, the stream is pulled downward by the descending flow of the liq. medium (e), and the stream is cut at the recesses. The filling substances C and D are covered with the film substances A and B by surface tension, and the cut droplet (f) is formed into a roundish seamless soft capsule 10 while descending in the descending flow of the liq. medium (e). The capsule is cooled, solidified, sent to a hopper 7 through a recovery tube 61, separated from the liq. medium (e) by a separator 70, supplied to a conveyor 9, and then dried.
The present invention relates to a medicament for drug abstinence and pain alleviation. The medicament comprises 0.5 to 10.0 mu g/ l to 20 ml of tetrodotoxin (TTX) and 0.0125 to 1.0% of an acetic acid injection with the pH value between 4 and 5, wherein procaine can also be added into the acetic acid to be made into a compound injection. The present invention provides a novel method for the eluting step and the regeneration step of activated carbon after the adsorption in the five steps of the TTX extraction process, namely that a solution with acetic acid and ethanol is used for eluting; then, acetic acid, an ethanol solution and water are used for washing a carbon column for regeneration. The steps can be simplified, and the yield can be improved. A preparation method for the injection has the steps that TTX is dissolved into an acetic acid solution, and the acetic acid solution is diluted into the desired concentration by water, or a procaine solution can also be added into the acetic acid solution to be prepared into a compound solution; the injection is obtained through boiling, cooling, filtering, bottling, final encapsulating and sterilizing. When used for terminal cancer analgesia, the medicament has the effective rate of 94.2%; when used for drug abstinence, the medicament has the withdrawal rate of 95 to 100%. The medicament of the present invention has no addiction and no toxic or side effect.
Disclosed is a 3,4-fused seven-membered heterocyclic oxindole, a synthesis method therefor and an application thereof. A structure of a 3,4-fused seven-membered nitrogen heterocyclic oxindole is provided in the present invention. A method for synthesizing same is also provided, comprising the following steps: reacting propargyl alcohol containing an isatin framework with a nucleophile under specific conditions to prepare a 3,4-fused seven-membered nitrogen heterocyclic oxindole. A pharmaceutical composition is provided in the present invention. Also provided in the present invention is an application of a 3,4-fused seven-membered nitrogen heterocyclic oxindole in the preparation of a drug for treating cancer. Provided in the present invention is a method for efficiently synthesizing 3,4-fused seven-membered nitrogen heterocyclic oxindoles having different structures. This is the first time achieving efficient synthesis of bioactive molecules containing both benzazepine and 3,4-fused heterooxidized oxindole structures on the basis of a hydrogen migration strategy.
BACKGROUND/AIM: Colorectal cancer (CRC) is the third most common cancer worldwide, and metastasis is strongly associated with poor prognosis in patients with CRC. We have previously found that the expression and phosphorylation of paxillin (PXN) play an important role in the metastatic potential of breast cancer. This study examined the potential role of PXN in CRC metastasis.
MATERIALS AND METHODS: Resected tumor specimens from 92 patients with CRC were subjected to immunohistochemical analysis of PXN levels. Three human CRC cell lines, HCT116, LoVo, and SW480 were used for scratch and transwell invasion assays to examine the effects of PXN over-expression. RNA sequencing was performed to obtain the expression profiles under PXN over-expression.
RESULTS: High levels of PXN were significantly correlated with advanced stage, higher carcinoembryonic antigen and carbohydrate antigen 19-9 levels, and poorer overall survival. The migration ability of CRC cells was enhanced by exogenous PXN over-expression, but this enhancement was not observed in cells harboring exogenously mutated PXN at Tyr31 or Tyr88 phosphorylation sites. In PXN-over-expressing cells, TNF-α signaling via NF-[Formula: see text]B was positively enriched.
CONCLUSION: PXN expression and phosphorylation at Tyr31 or Tyr88 may influence the migration and invasion of CRC cells. PXN expression and phosphorylation at Tyr31 or Tyr88 are promising targets for evaluating prognosis and treating CRC.